Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Plasmacytoma × daratumumab × Clear all

Phase

Phase 2 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 36 Recurrence 4 Smoldering Multiple Myeloma 2 Plasmacytoma 1 Immunoglobulin Light-chain Amyloidosis 1 Autoimmune Diseases of the Nervous System 1 Anti-N-Methyl-D-Aspartate Receptor Encephalitis 1

Interventions

Dexamethasone 2 daratumumab 1 Lenalidomide 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02136134 2025-08-29

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Phase 3 Completed

498 enrolled 15 charts

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡